SERACH RESULTS FOR" Development "
development, the demand for CDMOs is steadily increasing. This need for additional capacity is not only reflected in our Plant 4 pre-sales activity, but is also driving us to closely review the investment and construction of a second bio-campus in Songdo, Incheon. 3-Dimensional Expansion : Capacity / Geography / Portfolio Earlier this yera, we shared our '3-Dimensional Expansion' strategy to becoming a fully integrated global top-tier biopharmaceutical company, and I am proud to confirm we are keeping that promise even at this moment. In addition, Samsung Biologics will be proactive in fulfilling our commitment and responsibility to a better planet and social environment as signaled by the issuance of our first annual sustainability report during this past quarter. We will also continue to stay ahead of and respond to evolving market dynamics and client needs to maximize corporate and shareholder value. Thank you for your continued support. Sincerely, John Rim President and CEO, Samsung Biologics
development and manufacturing services according to our strict COVID-19 controls and management systems. Our supply chain management war room monitored and managed availability of critical materials around the clock, while our preemptive development of our Live Virtual Tour platform ensured our ability ot perform client due diligence and regulatory inspections amid worldwide travel restrictions, enabling us to sign additional CMO contracts for a total of 47 cumulative by the end of 2020. Our achievements in 2020 not only demonstrated innovation in the CDMO market but also strengthened our business competitiveness despite the COVID-19 pandemic. Samsung Biologics, I ask for your continued warm attention and support. Sincerely, also established a stable growth foundation by securing full contracts in Plants 1, 2, John Rim President and CEO, Samsung Biologicsand near-full contracts in plant 3. We also made a decisive investment to expand Plant 4 to respond to the accelerated supply/demand situation within the industry. Plant 4 will be the word's most productive facility, with a total of 256,000L, which is 76,000L larger than plant 3. in the CDO (contract Development) business, we successfully launched our proprietary cell line, "S-CHOice" in August. In october, we announced the opening of our R&D center in San Francisco, US. We will continue to evaluate expanding DP (fill finish) facilities to ensure client satisfaction by providing competitive end-to-end services. 2021 - The beginning of a new decade for Samsung Biologics, I ask for your continued warm attention and support. Sincerely, John Rim President and CEO, Samsung Biologics As announced at this year's JP Mogan conference, we are planning to expand our business in 3 aspects : capacity expansion, geography expansion, and scope expansion over the next 10 years: Capacity Expansion By acquiring Bio-campus Ⅱ and plant 4 expansion in Songdo play as game changer beyond CDMO champion Geography Expansion Expansion of CMO and CDO capacity oustide of Korea to maximize customer satisfaction and expand prospects. Scope Expansion Study from mAb based biologics to new potential growth momentum(eg. Cell/gene therapy, vaccine etc.) For the Next Decade 3-Dimensional Expansion - Business Expansion & Portfolio Diversification Source : JP Morgan Healthcare Conference 2021 Samsung Biologics will always advance forward and deliver on ever challenging goals as a CDMO Champion. As we celebrate our 10 year anniversary this year, we will not be complacent with our achievements, but instead commit ourselves even more to continuously innovating our process for superior client satisfaction. Through this, we will strive to increase both customer value while maximizing shareholder value. And we will continue to actively communicate with investors to inform on our business performance. In this new decade of Samsung Biologics, I ask for your continued warm attention and support. Sincerely, John Rim President and CEO, Samsung Biologics
development, to clinical and commercial manufacturing, offering fully integrated, one-stop services. for additional information regarding Plant 4, please visit our newly opened "Plant 4 Virtual Showroom", where you can also track its ongoing construction progress. Bio CMO/CDO/CRO Champing 2030 As a CDMO service provider, Samsung Biologics attained the largest total capacity within the shortest amount of time while ensuring top-notch quality services. We will continue to strengthen our competitive edge through technological innovation and new business development. We will also strive to ensure maximum client satisfaction, optimize shareholder value, and most importantly advance the industry in improving assessibility to healthcare and quality of life. We ask for your continued encouragement and support in buliding a better future with Samsung Biologics. Thank you, Tae Han Kim President & CEO, Samsung Biologics December 3rd, 2020
development and manufacturing according to our strict COVID-19 controls and management system. 2020 Q3 Revenue 2,746B KRW(QoQ 11% DOWN, YoY 49% UP) Operating Profit 565B KRW (QoQ 30% DOWN, YoY 139% UP) Profit Before Incom Tax 737B KRW (QoQ 9% UP, YoY 67% UP) Net Profit 561B KRW (QoQ 8% UP, YoY 27% UP) Manufacturing Contracts and Business Performance 4 additional contracts in Q3 11 cumulative contracts in 2020 thus far plant 4 Expansion(august) S-CHOiceTMLaunched(August) Continuing to Strengthen Business Competitiveness Towards Becoming a Super Value Company In August, we announced our Plant 4 expansion, which will have a capacity of 256,000L. With the Plant 4 expansion Samsung Biologics is proactively responding to changes in the global biopharmaceutical market and is strongly positioned as the global No.1 CMO based on production capacity. applying Super Value Company principles in the CDO(contract development)market, we continue to strengthen our competitive edge. Samsung Biologics successfully launched our own cell line, S-CHOiceTM, in August 2020. The S-CHOiceTM cell line results in shorter production times and price competitiveness for our clients. Additionally, to strengthen client satisfaction and bring our contract development services closer to global clients, we are launching a CDO R&D Center in San Francisco, California on October 29th(KST). I encourage you to attend the online grand opening ceremony of our CDO R&D Center. Please register through the link at the bottom of the letter. Samsung Biologics will contnue to innovate to provide qualiy services for clients to support them in their mission to advance life-saving therapies. Thank you, Tae Han Kim President & CEO, Samsung Biologics October 21, 2020 CEO IR Newsletter 2 뿐만 아니라 글로벌 거점과 고객사 확보 역량 강화를 위해 10월 29일 미국 San Francisco에 CDO R&D 센터를 오픈할 계획입니다. 온라인으로 진행되는 본 행사에 관심 있으신 투자자분들은 메일 하단의 '등록'을 통해 참석하실 수 있습니다. 삼성바이오로직스는 앞으로도 지속적인 혁신을 통해 빠른 속도로 양질의 서비스를 제공하며, 보다 높은 기업가치 창출을 위해 최선을 다하겠습니다. Super Value Company를 향한 삼성바이오로직스의 행보에 투자자 여러분들의 따뜻한 관심과 지속적인 성원을 부탁드립니다. 감사합니다. 2020년10월21일 삼성바이오로직스 대표이사 사장 김태한
파일 다운로드를 위해 뉴스레터 구독용 이메일 주소를 입력해주세요.
* 구독자라면 구독중인 이메일 주소를 입력해주세요.
뉴스레터 구독 서비스를 등록하시면 당사 뉴스룸에서 제공되는
삼성바이오로직스의 최신 소식과 관심 분야별 유용한 정보를 받아 보실 수 있습니다.
Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.
Samsung Biologics Confirms 'No Impact' of COVID-19 with Business Continuity Plan in EffectFebruary 25, 2020
-Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Anticancer Drugmore
-Naming Biopharmaceutical Products 1 Monoclonal Antibody Drugsmore
-Naming Biopharmaceutical Products 1 Monoclonal Antibody Drugsmore
-Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Agreement for Novel Targetmore
-Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Targetmore